Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. (Q40084202)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

title

Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Michael J Overman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

Gauri Varadhachary

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

Melanie B Thomas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

Masakazu Fukushima

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

Keizo Kuwata

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

Akira Mita

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

Robert A Wolff

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

Paulo M Hoff

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

Henry Xiong

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

James L Abbruzzese

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

publication date

5 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

Investigational New Drugs

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

445-454

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18528634 AND SRC:MED&resulttype=core&format=json

Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520).

8 January 2020

cites work

1 reference

12 December 2020

A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients

1 reference

12 December 2020

Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells

1 reference

12 December 2020

Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.

1 reference

12 December 2020

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

12 December 2020

A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.

1 reference

12 December 2020

Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.

1 reference

12 December 2020

Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.

1 reference

12 December 2020

Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells

1 reference

12 December 2020

An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.

1 reference

12 December 2020

A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells

1 reference

12 December 2020

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

12 December 2020

5-Fluorouracil: mechanisms of action and clinical strategies

1 reference

12 December 2020

Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies

1 reference

12 December 2020

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

12 December 2020